BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AST2303 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of AST2303\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06955988-2233@assetmemo.bio
DTSTAMP:20261121T005600Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:AST2303: Phase 1 readout est. (NCT06955988)
DESCRIPTION:AST2303\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A Study
  to Evaluate the Safety\, Tolerability\, Pharmacokinetics\, and Efficacy o
 f AST2303 Tablets (ABK3376 Tablets) in Patients With Advanced or Metastati
 c Non-Small Cell Lung Cancer\nEstimated primary completion: December 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/ast2303#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06955988
URL:https://assetmemo.bio/drug/ast2303#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
